NPY1R Antibodies

Neuropeptide Y receptor type 1 (NPY1R)

Receptor for neuropeptide Y and peptide YY.

The rank order of affinity of this receptor for pancreatic polypeptides is NPY > [Pro-34] PYY, PYY and [Leu-31, Pro-34] NPY > NPY (2-36) > [Ile-31, Gln-34] PP and PYY (3-36) > PP > NPY free acid.

.

Gene Information

Human
Gene Name:	NPY1R
Uniprot:	P25929
Entrez:	4886

Family

Belongs to:
G-protein coupled receptor 1 family

Alternative Names

neuropeptide Y receptor type 1; neuropeptide Y receptor Y1; NPY1R; NPY1-R; NPYR; NPYY1

Molecular Weight

Mass (kDA):
44.392 kDA

Genomic Context

Human
Location:	4q32.2
Sequence:	4; NC_000004.12 (163323962..163344832, complement)

Subcellular Localizations

Cell membrane; Multi-pass membrane protein.

Diseases

• Anxiety Disorders
• Nervousness
• Obesity
• Pathologic Vasoconstriction
• Hypertensive Disease
• Diabetes Mellitus
• Nerve Damage
• Pain
• Diabetes Mellitus, Non-insulin-dependent
• Hypertrophy
• Cardiovascular Diseases

• Schizophrenia
• Substance Withdrawal Syndrome
• Malnutrition
• Physiological Stress
• Psychotic Disorders
• Depressive Disorder

Interacting Proteins

• PYY

Pathways

• Vasoconstriction
• Energy Homeostasis
• Neurogenesis
• Sensitization
• System Development
• Feeding Behavior
• Localization
• Secretion
• Transport
• Aging
• Hypersensitivity
• Cardiovascular System Development
• Reflex

• Swimming
• Menarche
• Regulation Of Blood Pressure
• Cell Proliferation
• Chemokinesis
• Associative Learning
• Conjugation

PTMs

• Phosphorylation

Research Areas

• GPCR
• Neuroscience
• Neurotransmission

For details, visit:
bosterbio.com/bosterbio-gene-info-cards/NPY1R

Best Uses of the NPY1R Marker

There are numerous advantages to using the novel NPY1R marker for your research. You can submit your results for various species or applications and earn product credits. This biomarker is accessible to any scientist around the world. Here are a few benefits. These advantages include:

NPY1R is an innovative marker for cancer cells that are circulating

A recent study revealed that neuropeptide Y receptor Y1 (NPY1R) is a brand new marker of cancer cells that are circulating. The gene is expressed in high levels in cancer tissues , but at very low levels in healthy individuals. The expression of NPY1R was significantly higher in breast cancer patients as compared to controls. Furthermore, tumors with a high expression of NPY1R had shorter tumor-specific survival than tumors that had a low or absence of NPY1R.

To determine the presence of a small amount of cancerous cells, researchers used the nested QPCR. They used 1ml of cDNA mixed 1:120, and 0.2 mg/l of primers for the outer side to detect NYP1R. Using the paired samples from the Illumina HiSeq dataset, they calculated the differential expression ratio using the formula Q = 2-DDCt.

In MCF7 cells that were parental T47D, ZR75-1, and T47D cell lines, the protein expression of NPY1R was assessed. The cDNA libraries were processed and processed using the Digital Gene Expression Displayer program which identified 30,460 and 21,036 sequences. Of those, 23 were overexpressed genes, and the NPY1R was the most overexpressed. The researchers then used anti-NPY1R primary antibodies to determine the expression of proteins.

The NPY1R gene is associated with DNA infrared and cellular responses via the ATR pathway. It also influences the cell cycle. NPY1R also has a connection with amino acid metabolism and DNA repair. The NPY1R gene is not a reliable indicator of cancerous cells that are circulating however, it could be useful in the prediction of treatment response.

The soluble NPY1R protein can be found in many breast cancer patients. The receptor is expressed by osteoblasts, as well as bone marrow cells stromal cells. This protein can influence bone formation via anabolic effects on bone. Osteocytes cocultured in myeloma cells showed decreased expression of NPY1R. Osteocytes could play a role in the apoptosis process triggered by MM cells.

Additionally, NPY1R expression is increased in BC cell lines that have the ER receptor. Since estrogen and NPY interact to inhibit the growth of E2-stimulated cells in BC cells, the higher expression of NPY1R is a predictor of a patient's outcomes. It should allow circulating NPY to block tumor growth and improve endocrine therapy efficacy.

NPY1R has been associated with two novel signaling pathways in childhood obesity. Positive correlations have been discovered between TCF4 and NPY1R expression. These two proteins act on microRNA 4713 and cause lower levels of. Surprisingly, NPY1R expression in obese children is significantly higher than normal weight, but not as significant as the levels of normal weight and fracture group.

Extracellular vesicles (or EVs) are produced by a combination of tumor tissues. Although it is difficult to distinguish them from normal tissues, EVs can be used as a diagnostic indicator for pancreatic cancer. Additionally, circulation-based EVs contain tumor-specific proteins. Researchers discovered that circ IARS and Glypican-1 have a tumor-specific nature and can be used as diagnostic markers for pancreatic cancer.

A low-risk miRNA was also developed that targets three genes linked to the progression of breast cancer. This miRNA targets the gene SGOL1, which is which is a Shougoshin member. These genes aren't the only ones affected by hsamiR29c. It is also associated with the hsa–miR-42-3p gene, as well as the

It is a new marker for cancer cells circulating in the bloodstream.

A study of 142 patients suffering from breast cancer revealed that NPY1R expression was measured. It was significantly lower in EDR and TamR, T47D, T47D, ZR75-1 derivatives. However, NPY1R expression in MCF7 parental cell was significantly higher. Additionally, NPY1R expression was higher in ER+ BC, indicating that it might be a reliable marker for sensitization to endocrine treatment and response.

NPY1R is part of the larger G Protein-Coupled Receptor (GPCR) superfamily. The vast majority of GPCRs are not been discovered in breast cancer, but the Cancer Genome Atlas provides a significant BC proteomic as well as phosphoproteomic analysis. The study showed that NPY1R is significantly higher in Luminal A tumors than in Basal tumors.

The NPY1R gene was also linked to DNA infrared, as well as cellular response through ATR pathways. This protein is essential for the angiogenesis and proliferation of cancer cells. NPY1R is also involved in cell cycle signaling pathways. This discovery provides the basis for the identification of BC cell subtypes in relation to the expression of the NPY1R.

NPY1R is an attractive candidate to detect tumor cells that are circulating. The detection of circulating cancer cells is a method to detect and monitor the progression of disease. These cells are not detected by conventional diagnostic methods. In this study, the highly sensitive nested QPCR method is used to detect one breast cancer cell in 107. While qPCR-based tumor detection has greater sensitivity than conventional methods but it is constrained by the availability molecular markers.

Breast cancer patients have high levels of the NPY1R gene. This indicates its potential to be a blood marker peripheral for lymph node metastasis among breast cancer patients. The researchers also discovered that serum NPY1R levels were associated with the severity of tumors, necrosis, lymphovascular invasion and hormone receptor negativity. These findings suggest that ER+ breast cancer patients are the ones who have a higher NPY1R level. Multiple markers might be required to increase the sensitivity and specificity.

This gene has been associated with two signaling pathways in children. TCF4 as well as HEY1 are associated with NPY1R in obese patients. TCF4 and HEY1 also downregulate microRNA 4713 expression. Furthermore, GATA3 has decreased expression in obese children. However, their expression of NPY1R was not significantly different from the levels of non-obese patients.

The NPY1R gene is expressed in a variety of cell lines, parents cells and treatment for endocrine issues. It has been implicated in prostate cancer and various malignancies, where it has an important role in bone homeostasis. It is also involved in adrenal cortical tumors, suggesting a Y1R-mediated physiological function.

These new findings could help to develop therapeutic strategies for CC. Further research is required to determine which miRs are associated with obesity. These miRNAs are connected with obesity and adipose tissue. Identifying their regulation mechanisms could provide new treatments. However, it is important to note that the results obtained here are preliminary and require further validation in separate groups.

Presently, only a few biomarkers have been identified in cancer of the human. NPY1R and FAM83A-H have been identified, however both have oncogenic functions. Although clinical trials are not currently available for FAM83A/H members, the results suggest that they are connected and may be used together to treat different forms of cancer.

The creation of these biomarkers is based on utilization of a massive database of expression data that is derived from the Cancer Genome Anatomy Project (TCGA). The database has a huge amount of data from many different cancer cell varieties. The data was used by the authors to identify differentially expressed genes within both breast cancer cells and leukocytes. The marker gene that was chosen for the candidate was chosen by the gene that had the highest sequence odds ratio.

The findings showed that the presence of NPY1R is associated with a lower risk of cancer than other miRNAs. This is not surprising considering the fact that the gene encodes a protein that is involved in multiple pathways of cancer. The hsa–miR–129c protein targets SGOL1 which is a member of the Shougoshin clan. It also targets the transcription factor II-I GTF21.